IMPACT BIOMEDICAL INC. (IBO) Financial Statements
IMPACT BIOMEDICAL INC. (IBO) reported trailing twelve-month revenue of $35000 and net income of $789000 as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$508000.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IBOIMPACT BIOMEDICAL INC.Follow IBO — free
—
Price chart with a free account
- Market cap
- 30.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 6 Nov, in 13 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2022 Dec 22 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Revenue | 0.1 | 0.0 | 0.0 | |
| Gross profit | — | -0.4 | — | |
| Research & development | — | 0.3 | 0.3 | |
| Operating income | — | -4.3 | -5.1 | |
| Pre-tax income | -7.9 | -14.5 | -1.8 | |
| Income tax | -0.6 | -2.6 | — | |
| Net income | — | -11.8 | 0.8 | |
| Diluted EPS ($) | — | -0.38 | 11.11 |
USD millions · SEC XBRL
IMPACT BIOMEDICAL INC. — questions
- What is IMPACT BIOMEDICAL INC.'s revenue?
- $35000 over the twelve months to 2026-06-30, from its 10-Q and 10-K filings.
- What is IMPACT BIOMEDICAL INC.'s net income?
- $789000 over the twelve months to 2026-06-30.
- What is IMPACT BIOMEDICAL INC.'s free cash flow?
- -$508000 over the twelve months to 2026-06-30.
- What are IMPACT BIOMEDICAL INC.'s diluted earnings per share?
- $11.11 over the twelve months to 2026-06-30.
Every figure on this page comes from IMPACT BIOMEDICAL INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.